HEK293-ACE2-NRP1 Overexpression Stable Cell Line

Product Description

Advance SARS-CoV-2 research with a ready-to-use stable cell line that overexpresses both ACE2 and NRP1, a facilitator of ACE2-mediated SARS-CoV-2 cell entry

• Leverage SBI’s robust lentivector expression technology to safely study SARS-CoV-2 cell entry
• Ready-to-use stable cell line overexpresses both the ACE2 receptor as well as neuropilin-1 (NRP1), a potentiator of ACE2-mediated SARS-CoV-2 cell entry
• An NRP1 overexpression lentivector is also available as plasmid and pre-packaged virus
• An ACE2 overexpression lentivector is also available as plasmid and pre-packaged virus

The HEK293 ACE2 NRP1 Overexpression Stable Cell Line is one example, which we quickly developed in response to publications showing that neuropilin-1 (NRP1) enhances ACE2-mediated cell entry of SARS-CoV-2 [1, 2]. With the HEK293 Ace2 NRP1 Overexpression Stable Cell Line, you can quickly get similar studies running in your own lab, whether to further analyze binding and cell entry, discover inhibitors, or more.

The HEK293 ACE2 NRP1 Overexpression Stable Cell Line takes advantage of our our robust pCDH-CMV-MCS-EF1α-Neo Cloning and Expression Lentivector (Cat.# CD514B-1-SBI), delivering NRP1 expression from the CMV promoter with a separate EF1α promoter driving the expression of the neomycin resistance gene for selection.

Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.